Medicamentos actuales y emergentes “Existen muchas opciones terapéuticas disponibles, pero sigue siendo un desafío hacer coincidir el medicamento correcto con el paciente correcto” Recuerdo en mi memoria ... es junio de 2016, y acabo [...]
Cancer and COVID both leave us feeling so out of control. Grief expert Claire M. Schwartz shares her thoughts on the similarities of the trauma of cancer & pandemics and offers some advice on coping.
As posted in the ASCO Daily News, Dr. George Demetri, has received recognition for his work in developing targeted TKIs for GIST.
LRG’s Senior Director of Research, Pete Knox has summarized the ten key studies relating to GIST that are being presented at the American Society of Clinical Oncology's Annual meeting. ASCO20 is virtual this year.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Marlene Nei shares her story.
May is Mental Health Awareness Month and this year it takes on new dimensions due to the COVID-19 health pandemic for those already coping with mental illness as well as those adversely affected by the the struggles the pandemic has created.
The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Although the ASCO (American Society for Clinical Oncology) will be a virtual meeting this year, The Life Raft Group continues to be at the forefront in collaborating in efforts to improve treatment for cancer patients. This year, two important abstracts will be presented online that illustrate these efforts.
